Improving Cognitive Assessment and Reducing Burden for Clinical Trials in People with Schizophrenia

Cognitive dysfunction is a central feature of schizophrenia and leads to significant impacts on patient function and quality of life. As such, addressing cognitive impairment is a major unmet medical need in the development of therapies for people with schizophrenia.

Cogstate supports sponsors in these efforts by providing valid, sensitive, and reliable digital/computerized assessment that comprehensively evaluates cognitive domains of relevance to people with schizophrenia, while offering a significant reduction in patient and trial burden compared to other assessment tools.

Download the fact sheet below to learn more.

Download Fact Sheet

Back to Fact Sheets